

ONLINE SUPPLEMENT

**The Monocyte Chemotactic Protein-1 — Interleukin-6 — Osteopontin Pathway of Intra-
Aneurysmal Tissue Healing**


**Koji Hosaka, PhD, Kelley Rojas, BS, Hanain Z Fazal, BS, Matheus B Schneider, BS, Jorma
Shores, BS, Vincent Federico, BS, Matthew McCord, BS, Li Lin, BS and Brian Hoh, MD.**

Department of Neurosurgery, University of Florida

Supplemental Table I. Immunostaining of human coiled aneurysms and control arteries

Sample	MCP-1	IL-6	OPN
Human Coiled Aneurysm #1	+	+	+
Human Coiled Aneurysm #2	+	+	+
STA #1	-	-	-
STA #2	-	-	-
STA #3	-	-	-
STA #4	-	-	-
STA #5	-	-	-

STA: Superficial Temporal Artery, +: positive, -: negative



Supplemental Figure I. Quantification of MCP-1, IL-6 and OPN expression in human coiled aneurysms and control arteries.

Immunofluorescent staining and analyses of human coiled aneurysms (n=2) and control STA (n=5) samples were performed. MCP-1, IL-6 and OPN expression were observed in human coiled tissues, but not in STA samples (MCP-1: 54.5 +/- 22.5 vs 2.2 +/- 1.6; IL-6: 23.5 +/- 8.5 vs 1.6 +/- 0.9; OPN: 16.0 +/- 8.0 vs 1.4 +/- 0.5). Representative images are shown in Figure 2 (MCP-1 and IL-6) and Figure 6 (OPN). STA: superficial temporal artery

Stroke Online Supplement

Table I. Checklist of Methodological and Reporting Aspects for Articles Submitted to *Stroke* Involving Preclinical Experimentation

Methodological and Reporting Aspects	Description of Procedures
Experimental groups and study timeline	<ul style="list-style-type: none"> <input checked="" type="checkbox"/> The experimental group(s) have been clearly defined in the article, including number of animals in each experimental arm of the study. <input checked="" type="checkbox"/> An account of the control group is provided, and number of animals in the control group has been reported. If no controls were used, the rationale has been stated. <input checked="" type="checkbox"/> An overall study timeline is provided.
Inclusion and exclusion criteria	<ul style="list-style-type: none"> <input checked="" type="checkbox"/> A priori inclusion and exclusion criteria for tested animals were defined and have been reported in the article.
Randomization	<ul style="list-style-type: none"> <input checked="" type="checkbox"/> Animals were randomly assigned to the experimental groups. If the work being submitted does not contain multiple experimental groups, or if random assignment was not used, adequate explanations have been provided. <input checked="" type="checkbox"/> Type and methods of randomization have been described. <input checked="" type="checkbox"/> Methods used for allocation concealment have been reported.
Blinding	<ul style="list-style-type: none"> <input checked="" type="checkbox"/> Blinding procedures have been described with regard to masking of group/treatment assignment from the experimenter. The rationale for nonblinding of the experimenter has been provided, if such was not feasible. <input checked="" type="checkbox"/> Blinding procedures have been described with regard to masking of group assignment during outcome assessment.
Sample size and power calculations	<ul style="list-style-type: none"> <input checked="" type="checkbox"/> Formal sample size and power calculations were conducted based on a priori determined outcome(s) and treatment effect, and the data have been reported. A formal size assessment was not conducted and a rationale has been provided.
Data reporting and statistical methods	<ul style="list-style-type: none"> <input checked="" type="checkbox"/> Number of animals in each group: randomized, tested, lost to follow-up, or died have been reported. If the experimentation involves repeated measurements, the number of animals assessed at each time point is provided, for all experimental groups. <input checked="" type="checkbox"/> Baseline data on assessed outcome(s) for all experimental groups have been reported. <input checked="" type="checkbox"/> Details on important adverse events and death of animals during the course of experimentation have been provided, for all experimental arms. <input checked="" type="checkbox"/> Statistical methods used have been reported. <input checked="" type="checkbox"/> Numeric data on outcomes have been provided in text, or in a tabular format with the main article or as supplementary tables, in addition to the figures.
Experimental details, ethics, and funding statements	<ul style="list-style-type: none"> <input checked="" type="checkbox"/> Details on experimentation including stroke model, formulation and dosage of therapeutic agent, site and route of administration, use of anesthesia and analgesia, temperature control during experimentation, and postprocedural monitoring have been described. <input checked="" type="checkbox"/> Different sex animals have been used. If not, the reason/justification is provided. <input checked="" type="checkbox"/> Statements on approval by ethics boards and ethical conduct of studies have been provided. <input checked="" type="checkbox"/> Statements on funding and conflicts of interests have been provided.